Drug Database
BE

beclometasone dipropionate (Qvar RediHaler / Qvar BAI)

✓ Approved

Teva Pharmaceutical Industries Ltd. · NR3C1 · Small Molecule

What is beclometasone dipropionate?

beclometasone dipropionate is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via inhaled.

Drug Profile

Brand NamesQvar RediHaler, Qvar BAI
CompanyTeva Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteInhaled
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Mechanism of Action

Molecular Targets

beclometasone dipropionate acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

beclometasone dipropionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

Related Research Articles

PubMedClinical therapeutics2026-05-13

Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate/Formoterol Fumarate.

Almeida Mafalda M, Salvadori Michela M, Corradi Massimo M, De Ridder Thomas T et al.

Use of high global warming potential propellants (eg, 1,1,1,2-tetrafluoroethane [HFA-134a]) in pressurized metered-dose inhalers (pMDIs) is being phased down. Extrafine formulation of beclometasone dipropionate (BDP)/formoterol fumarate (FF), approved for the treatment of asthma or chronic obstructive pulmonary disease via HFA-134a propellant pMDI, is being reformulated using the low global warming potential propellant 1,1-difluoroethane (HFA-152a). Two studies compared BDP/FF pharmacokinetics delivered via pMDI using HFA-152a versus HFA-134a. Both studies (N = 90 in each) were single-dose (4 actuations), randomized, double-blind, 4-way crossover, in healthy volunteers. The first evaluated bioequivalence of BDP/FF 100/6 µg per actuation (ie, medium strength in terms of BDP), with and without a spacer; the second evaluated BDP/FF 200/6 µg per actuation (high-strength), with and without a spacer. The primary variables were AUC0-t, Cmax, and Tmax for BDP, beclometasone-17-monopropionate (active metabolite of BDP), and formoterol, as well as AUC between time 0 and 30 minutes after dose (AUC0-30 min) for formoterol. Bioequivalence was concluded for Cmax, AUC0-t, and formoterol AUC0-30 min if the 90% CI of the ratio of geometric means for the 2 formulations was contained between 80% and 125%. Bioequivalence of the 2 propellants was demonstrated in both studies for BDP, beclometasone-17-monopropionate, and formoterol Cmax and AUC0-t, as well as for formoterol AUC0-30 min, with and without the spacer, with no differences between formulations for Tmax. Bioequivalence was formally demonstrated between the BDP/FF HFA-134a and HFA-152a formulations.

PMID 42120272
Read full article →
PubMedLeukemia & lymphoma2026-05-12

Systemic corticosteroid-free beclomethasone dipropionate monotherapy for mild acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Yoshino Nozomu N, Kimura Shun-Ichi SI, Shiraishi Natsuo N, Yamamoto Kaisuke K et al.

Systemic corticosteroids are the standard initial therapy for gastrointestinal graft-versus-host disease (GI-GVHD), but are associated with increased infectious risk and potential attenuation of graft-versus-leukemia effects. Beclomethasone dipropionate (BDP) has minimal gastrointestinal absorption and may provide localized efficacy, but evidence for monotherapy is limited. We retrospectively analyzed 37 patients who underwent first allogeneic hematopoietic cell transplantation and received oral BDP as initial monotherapy for acute GI-GVHD. Treatment response was assessed at days 28 and 56, and treatment failure was defined as initiation of systemic corticosteroids. All patients had stage 0-1 disease. Upper and lower GI-GVHD were observed in 24 (64.9%) and 13 (35.1%) patients, respectively. Response rates at days 28 and 56 were 62.9% and 65.6%. Treatment failure occurred more frequently in patients with lower GI-GVHD, female-to-male transplantation, and reduced-intensity conditioning. BDP monotherapy may be effective for selected patients with mild GI-GVHD, although careful monitoring is required in high-risk populations.

PMID 42117673
Read full article →
PubMedDermatology and therapy2026-05-03

Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial.

Cai Lin L, Zhang Furen F, Zhang Guoqiang G, Ding Yangfeng Y et al.

The aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) is an efficacious topical treatment for psoriasis. This study evaluated the efficacy of Cal/BD foam versus ointment in Chinese patients, on the basis of investigator-assessed and patient-reported outcomes (PROs) from a 4-week clinical trial, including post hoc analyses after 2 weeks of treatment. A randomized, investigator-blind, active-controlled, parallel-group phase 3 trial was conducted in China. Native Chinese adults (≥ 18 years) with plaque psoriasis involving 2-30% of the body surface area (BSA), with at least mild disease severity according to the Physician's Global Assessment (PGA), and modified Psoriasis Area and Severity Index (mPASI) ≥ 2 were randomized 1:1 to receive either Cal/BD foam or ointment once daily for a 4-week treatment period. Efficacy was assessed at weeks 0, 2, and 4 using mPASI, PGA, BSA, Dermatology Life Quality Index (DLQI), Psoriasis Symptom Inventory (PSI), and Subject's Global Assessment of disease severity (SGA). A total of 302 patients were randomized to each treatment. Both groups had clinically meaningful improvements across all outcome measures from baseline to week 2, with sustained or further improvements at week 4. For Cal/BD foam-treated patients, mean change from baseline in mPASI was -59.87% at week 2 (versus ointment: -54.59%; P = 0.010) and -74.69% at week 4 (versus ointment: -70.22%; P = 0.043). Other investigator-assessed outcomes based on mPASI and PGA showed statistically significant treatment differences favoring Cal/BD foam at week 4. Improvements in PROs (DLQI, PSI, and SGA) were numerically slightly greater with Cal/BD foam than ointment, though not statistically significant. For Cal/BD foam-treated patients, mean change from baseline in DLQI was -3.9 at week 2 (versus ointment: -3.7; P = 0.5012) and -5.5 at week 4 (versus ointment: -5.3; P = 0.5119). Cal/BD foam showed rapid onset of action with clinically meaningful improvements in signs, symptoms, and quality of life in Chinese patients with plaque psoriasis. ClinicalTrials.gov: NCT05919082. Plaque psoriasis is the most common type of psoriasis, a chronic disease affecting the skin and other body systems. Plaques are thick, scaly patches of skin that can be itchy and painful, limiting patients' everyday activities. Plaque psoriasis has a major impact on quality of life, comparable with the impact of other chronic diseases such as cancer and heart disease. Many treatments, such as creams, tablets, and injections, can improve plaque psoriasis, but they do not always work well for everyone. In a clinical trial in China, we tested two treatments-a foam and an ointment-that have the same amount of two active ingredients: calcipotriol (Cal) and betamethasone dipropionate (BD). The goal was to find out if Cal/BD foam, which is the newer treatment, worked as well as Cal/BD ointment in Chinese men and women with plaque psoriasis. The trial participants were randomly distributed into two groups, each with 302 participants. One group applied Cal/BD foam on their plaques and the other group applied Cal/BD ointment, both once daily for 4 weeks. Both groups had meaningful improvements in psoriasis signs and symptoms as well as quality of life already after 2 weeks, with sustained or further improvements after 4 weeks. Overall, the improvements were slightly greater with Cal/BD foam than with Cal/BD ointment.

PMID 42070197
Read full article →
PubMedClinical and experimental dermatology2026-04-29

Patient and clinician reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, non-interventional, multicentre PRO-SCALP study.

López Estebaranz Jose Luis JL, Bewley Anthony A, Pinter Andreas A, Galván Jordi J et al.

The novel cream formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion technology (CAL/BDP PAD-cream), has shown promising results on psoriasis in phase 3 clinical trials. However, real-world data on scalp are limited. To assess clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) of CAL/BDP PAD-cream in adults with mild-to-moderate scalp psoriasis under real-world conditions in Europe. PRO-SCALP is a prospective, non-interventional, multicentre, cohort study conducted between June 2023 and October 2024 in Germany, Spain and the United Kingdom. Data were collected at baseline and Week 8 (end of study, EOS). PROs included Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9), Scalpdex questionnaire, Worst Itch-Numerical Rating Scale (WI-NRS), sleep disturbances, Psychosocial Effects of Scalp Psoriasis Questionnaire and adherence. ClinROs included treatment satisfaction and physician global assessment of scalp (scalp-PGA) and scalp-modified Psoriasis Area and Severity Index (S-mPASI). 253 patients (mean age: 47.9 years; 65.2% females) had evaluable data. 59.9% of them reported high adherence (visual analogue scale score 80-100). At EOS, mean (standard deviation) global satisfaction (TSQM-9) was 76.0 (21.6) and 77.6% of patients achieved a scalp-PGA score of 0/1 (clear/almost clear). Moreover, 68.4% achieved scalp-PGA success (scores of 0/1 and ≥2-point improvement). WI-NRS, S-mPASI and Scalpdex scores improved significantly (p<0.0001) from baseline to EOS. Sleep patterns and psychosocial outcomes also improved. CAL/BDP PAD-cream is associated with high treatment satisfaction and improved clinical outcomes and quality of life in the real-world management of scalp psoriasis.

PMID 42052895
Read full article →
PubMedInternational journal of pharmaceutics2026-04-16

The effect of mouthpiece shape and size on low-GWP metered dose inhaler performance.

Duke Daniel J DJ, Wang Haiqiao H, Rao Lingzhe L, McRae Ethan E et al.

Design of the mouthpiece of a pressurised metered dose inhaler is generally informed by patient needs, followed by manufacturing and product differentiation considerations. However, relatively few studies have investigated whether the size and shape of the mouthpiece might be altered to adjust drug deposition. The motivation for such adjustment is the impending switch to low-global warming potential (GWP) propellants with differing plume geometry and deposition characteristics. In this study we investigate how the size and shape of the mouthpiece affects aerodynamic particle size distribution and spray plume geometry for a model solution formulation of 2 mg/mL beclomethasone dipropionate in 8% w/w ethanol. Six mouthpiece designs were investigated for a control formulation with HFA-134a propellant. A partial parametric study was also conducted for formulations in HFA-152a and HFO-1234ze(E) propellants. The mouthpiece shape had a statistically significant effect on mouthpiece and throat deposition as expected, but with no statistically significant change at smaller particle sizes, since aerosol maturation is primarily influenced by formulation and actuator orifice design. Significance was reduced for low-GWP propellants using the larger mouthpiece designs. Analysis of ex-mouthpiece plume geometry revealed that the mouthpiece shape and size had no significant effect on the ensemble-average plume geometry, but did have an effect on the degree of shot-to-shot variation between actuations. These results show that mouthpiece design may be a useful means of adjusting the balance between throat and mouthpiece deposition without altering APSD at the respirable size range when formulating low-GWP pMDIs to achieve equivalent APSD outcomes to existing systems.

PMID 41985600
Read full article →
PubMedRespiratory medicine2026-04-09

Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/formoterol fumarate/glycopyrronium: The TRECOS study.

Singh Dave D, Mancini Lorenzo L, Melis Giada G, Cortellini Mauro M et al.

Propellants currently used in pressurised metered-dose inhalers (e.g., HFA-134a) are being replaced by low global warming potential alternatives, including HFA-152a. This study aimed to assess the bronchoconstriction potential and the safety and tolerability of triple combination beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) HFA-152a pMDI compared to BDP/FF/G HFA-134a pMDI. Adults with moderate-to-severe controlled asthma received BDP/FF/G HFA-134a pMDI for a two-week run-in, then were randomised 1:2 to either continue the HFA-134a pMDI formulation or switch to the HFA-152a pMDI formulation, both for 12 weeks. The primary objective was to compare the bronchoconstriction potential of BDP/FF/G HFA-152a vs HFA-134a in terms of the relative change from pre-dose in forced expiratory volume in 1 s (FEV1) at 10 min post-dose on Day 1. Safety and tolerability assessments included adverse event occurrence. Of 553 patients randomised to treatment, 539 (97.5%) completed the study (356/368 [96.7%] and 183/185 [98.9%] with the HFA-152a and HFA-134a formulations, respectively). There was no difference between the two groups for the primary endpoint, with an adjusted mean (95% confidence interval) HFA-152a vs HFA-134a difference of -1.143% (-2.769%, 0.483%). A total of 19.3% patients experienced adverse events with the HFA-152a formulation (71/368) compared to 27.6% with the HFA-134a formulation (51/185); most events with both formulations were mild or moderate in severity. Overall, transitioning to the low global warming potential HFA-152a formulation had no impact on the safety and tolerability of BDP/FF/G, with the positive effect on lung function comparable to the original HFA-134a formulation.

PMID 41951188
Read full article →

+3721 more articles available with a free account

Sign up free to view all articles →

Ask about beclometasone dipropionate